W
Won Ki Kang
Researcher at Samsung Medical Center
Publications - 385
Citations - 18420
Won Ki Kang is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Cancer & Capecitabine. The author has an hindex of 59, co-authored 368 publications receiving 14746 citations. Previous affiliations of Won Ki Kang include Sungkyunkwan University & Samsung.
Papers
More filters
Journal ArticleDOI
Clinical outcome of gastric cancer patients with bone marrow metastases
Hyo Song Kim,Seong Yoon Yi,Hyun Jung Jun,Jeeyun Lee,Joon Oh Park,Young Suk Park,Junho Jang,Hee Jin Kim,Young-Hyeh Ko,Ho Yeong Lim,Won Ki Kang +10 more
TL;DR: It is suggested that gastric cancer patients with bone marrow metastases should receive more tailored therapies according to different risk factors in order to enhance survival.
Journal ArticleDOI
Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Jinny Park,Park Bb,Jee Youn Kim,Se-Hoon Lee,Soon Il Lee,Ho Young Kim,Jung Han Kim,Se Hoon Park,Kyung Eun Lee,Joon Oh Park,Kihyun Kim,Chul Won Jung,Young Suk Park,Young-Hyuck Im,Won Ki Kang,Mark Hong Lee,Keunchil Park +16 more
TL;DR: Gefitinib demonstrated significant antitumor activity and a favorable tolerability profile in this series of NSCLC patients with poor prognosis.
Journal ArticleDOI
Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.
Hong-Hee Won,Hong-Hee Won,Jeeyun Lee,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Won Ki Kang,Jong-Won Kim,Soo-Youn Lee,Se Hoon Park +9 more
TL;DR: The authors performed a genome‐wide association analysis of patients with colon cancer who received oxaliplatin‐based chemotherapy to identify potential genetic markers for severe oxaliPlatin‐induced chronic peripheral neuropathy (OXCPN).
Journal ArticleDOI
High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma
Jeeyun Lee,Paul Van Hummelen,Christina Go,Emanuele Palescandolo,Jiryeon Jang,Ha Young Park,So Young Kang,Joon Oh Park,Won Ki Kang,Laura E. MacConaill,Kyoung-Mee Kim +10 more
TL;DR: Using high throughput mutation screening platform, it was identified that PIK3CA mutations were the most frequently observed target for gastric adenocarcinoma.
Journal ArticleDOI
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
Jeeyun Lee,Joon Oh Park,Won Seog Kim,Se Hoon Park,Keon Woo Park,Moon Seok Choi,Joon Hyoek Lee,Kwang Cheol Koh,Seung Woon Paik,Byung Chul Yoo,Jae-Won Joh,Kihyun Kim,Chul Won Jung,Young Suk Park,Young-Hyuck Im,Won Ki Kang,Mark Hong Lee,Keunchil Park +17 more
TL;DR: Combination chemotherapy with doxorubicin and cisplatin in metastatic HCC patients showed modest antitumor activity with relatively tolerable adverse effects, comparable to those found in other phase II trials, but the search for the optimal chemotherapy should be continued.